French consensus procedure for neuropsychological assessment in multiple sclerosis.

Cognitive assessment French consensus Multiple sclerosis

Journal

Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R

Informations de publication

Date de publication:
12 Jul 2024
Historique:
received: 06 02 2024
revised: 23 05 2024
accepted: 20 06 2024
medline: 14 7 2024
pubmed: 14 7 2024
entrez: 13 7 2024
Statut: aheadofprint

Résumé

Cognitive impairment is one of the invisible symptoms of Multiple sclerosis (MS), which could be associated with depression, unemployment, reduced social interaction, inability to drive, and compromised quality of life. Moreover, the presence of cognitive impairment can be considered as a long-term prognostic factor and in the follow-up of disability. So, cognitive assessment is a crucial element in clinical follow-up of patients with MS (pwMS). International recommendations mention the use of the Brief International Cognitive Assessment in MS (BICAMS). The BICAMS, that has been recently validated in French is a brief non-exhaustive assessment, developed as a short screening battery, hence needing other supplemented tests. The present paper aims to propose a consensus, approved by expert French consensus from the Cognition group of the SF-SEP (http://sfsep.org [Société Francophone de la Sclérose en Plaques]), for cognitive assessment of pwMS suggesting the tools that should be used in order to apprehend the other cognitive impairments that could appear in MS.

Identifiants

pubmed: 39003098
pii: S0035-3787(24)00558-7
doi: 10.1016/j.neurol.2024.06.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Masson SAS. All rights reserved.

Auteurs

C Jougleux (C)

Service de neurologie et pathologies neuro-inflammatoires, Clinique neurologique, CRC SEP, CHU de Lille, Lille, France. Electronic address: caroline.jougleux@chu-lille.fr.

H Joly (H)

Service de neurologie, CHU Pasteur 2, CRC SEP, Nice, France; UR2CA-URRIS, université Nice Côte d'Azur, Nice, France; CNRS, IMoPA, université de Lorraine, Nancy, France.

H Brissard (H)

CNRS, IMoPA, université de Lorraine, Nancy, France; Service de neurologie, CHRU de Nancy, Nancy, France.

B Lenne (B)

Groupement des hôpitaux de l'institut catholique de Lille (GHICL), Neurology Department, Lille, France.

S François (S)

Service de neurologie, CHU de Nantes, Nantes, France.

F Hamelin (F)

Structure régionale NeuroSEP Synapse, Le Vésinet, France.

N Derache (N)

Department of Neurology, centre hospitalier universitaire de Caen Normandie, Caen, France.

J Morin (J)

Service de neurologie pathologie inflammatoire du système nerveux central, CRC SEP, CHU Pellegrin, CHU de Bordeaux, Bordeaux, France.

F Reuter (F)

Service de neurologie, hôpital de la Timone, AP-HM, pôle de neurosciences cliniques, Marseille, France; CEMEREM, Aix Marseille université, CNRS, CRMBM, UMR 7339, Marseille, France.

R Colamarino (R)

Service de neurologie, CH d'Antibes, Antibes, France.

A Ruet (A)

Service de neurologie pathologie inflammatoire du système nerveux central, CRC SEP, CHU Pellegrin, CHU de Bordeaux, Bordeaux, France; Inserm U1215, Neurocentre Magendie, université de Bordeaux, Bordeaux, France.

Classifications MeSH